ValuEngine Upgrades Amicus Therapeutics (NASDAQ:FOLD) to Buy

ValuEngine upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a report issued on Wednesday morning, ValuEngine reports.

Several other analysts have also recently weighed in on FOLD. BidaskClub upgraded Amicus Therapeutics from a hold rating to a buy rating in a report on Thursday, November 21st. Zacks Investment Research upgraded Amicus Therapeutics from a hold rating to a buy rating and set a $9.25 price target on the stock in a report on Monday, November 4th. Cantor Fitzgerald reiterated an overweight rating on shares of Amicus Therapeutics in a report on Thursday, October 17th. Cowen set a $31.00 target price on Amicus Therapeutics and gave the company a buy rating in a report on Thursday, October 10th. Finally, HC Wainwright reiterated a buy rating and issued a $20.00 target price on shares of Amicus Therapeutics in a report on Thursday, November 21st. Ten equities research analysts have rated the stock with a buy rating, Amicus Therapeutics currently has a consensus rating of Buy and a consensus target price of $17.97.

NASDAQ:FOLD opened at $10.48 on Wednesday. The stock has a market cap of $2.64 billion, a P/E ratio of -7.88 and a beta of 1.58. The company has a current ratio of 6.20, a quick ratio of 6.10 and a debt-to-equity ratio of 0.36. The stock’s 50-day moving average is $8.93 and its 200-day moving average is $10.51. Amicus Therapeutics has a 1-year low of $7.11 and a 1-year high of $14.61.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Monday, November 11th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.32) by $0.08. The company had revenue of $48.80 million for the quarter, compared to analysts’ expectations of $48.05 million. Amicus Therapeutics had a negative return on equity of 62.61% and a negative net margin of 216.02%. The business’s quarterly revenue was up 136.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.84) earnings per share. As a group, equities analysts forecast that Amicus Therapeutics will post -1.27 EPS for the current year.

In other Amicus Therapeutics news, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $10.05, for a total value of $201,000.00. Following the transaction, the chief executive officer now directly owns 770,194 shares of the company’s stock, valued at $7,740,449.70. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO John F. Crowley sold 14,500 shares of the business’s stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $8.01, for a total value of $116,145.00. Following the completion of the transaction, the chief executive officer now directly owns 735,694 shares in the company, valued at $5,892,908.94. The disclosure for this sale can be found here. Insiders sold 114,500 shares of company stock worth $1,088,345 over the last quarter. 2.50% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of FOLD. First Trust Advisors LP acquired a new position in Amicus Therapeutics in the first quarter valued at approximately $635,000. Strs Ohio lifted its stake in Amicus Therapeutics by 75.0% in the second quarter. Strs Ohio now owns 18,900 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 8,100 shares during the period. Quantitative Systematic Strategies LLC lifted its stake in Amicus Therapeutics by 138.3% in the second quarter. Quantitative Systematic Strategies LLC now owns 66,532 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 38,608 shares during the period. Rothschild & Co. Asset Management US Inc. lifted its stake in Amicus Therapeutics by 2.9% in the second quarter. Rothschild & Co. Asset Management US Inc. now owns 1,534,423 shares of the biopharmaceutical company’s stock valued at $19,150,000 after buying an additional 43,483 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its stake in Amicus Therapeutics by 6.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 101,030 shares of the biopharmaceutical company’s stock valued at $1,261,000 after buying an additional 5,915 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Read More: What is a back-end load?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit